...
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Plasma Exchange as a Therapeutic Modality in a Rare Case of Cryptogenic New Onset Refractory Status Epilepticus (NORSE) ED33-ED34
【24h】

Plasma Exchange as a Therapeutic Modality in a Rare Case of Cryptogenic New Onset Refractory Status Epilepticus (NORSE) ED33-ED34

机译:在罕见的隐源性新发病难治性癫痫持续状态(NORSE)ED33-ED34中,血浆置换作为一种治疗方式

获取原文
           

摘要

Refractory Status Epilepticus (RSE) not responding to any therapy and not associated with any aetiology has been termed as New Onset Refractory Status Epilepticus (NORSE). Guidelines for optimal management of cryptogenic NORSE are not clearly defined so far in the literature. Other than common medication, use of high-dose steroids, IV immune globulins, and plasma exchanges in NORSE of unknown aetiology have been scarcely described. Immunomodulatory therapy like plasmapheresis is based on the fact that a pathological substance exists in the plasma that contributes to the disease process and its symptoms, which gets removed. We report a case of young female patient diagnosed as NORSE who responded to treatment with plasma exchange after becoming refractory to antiepileptic therapy and treatment with anaesthetic agents for recurrent seizers.
机译:对任何疗法无反应且与任何病因无关的顽固性癫痫持续状态(RSE)被称为新发作的顽固性癫痫持续状态(NORSE)。迄今为止,文献中还没有明确定义隐源性NORSE的最佳管理指南。除了普通药物外,几乎没有描述在病因不明的NORSE中使用大剂量类固醇,IV免疫球蛋白和血浆置换。诸如血浆置换的免疫调节疗法是基于这样的事实,即血浆中存在有助于疾病进程及其症状的病理物质,这种病理物质被清除。我们报告了一例被诊断为NORSE的年轻女性患者,该患者对抗癫痫药和麻醉剂对复发性癫痫发作难以治疗后对血浆置换治疗产生了反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号